Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Gritstone Oncology. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Gritstone Oncology's earnings available for a low price, and how does
this compare to other companies in the same industry?
Gritstone Oncology is not considered high growth as it is expected to be loss making for the next 1-3 years.
Gritstone Oncology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Gritstone Oncology's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Gritstone Oncology's finances.
The net worth of a company is the difference between its assets and liabilities.
Gritstone Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Gritstone Oncology's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Gritstone Oncology's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 6.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph.D., co-founded Gritstone Oncology Inc. and has been its Chief Executive Officer and President since September 2015. Dr. Allen advises Epic Sciences (La Jolla, CA). He Co-founded Clovis Oncology, Inc. in April 20, 2009 and served as its Chief Medical officer and Executive Vice President of Clinical & Pre-Clinical Development from April 20, 2009 to August 2015. He served as the Chief Medical Officer of Pharmion LLC since May 18, 2006 and served as its Executive Vice President since August 2006. He served as a Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation from 2004 to 2006. He served as Global Project Head in Abbott Laboratories' oncology franchise and he progressed through positions of increasing responsibility at McKinsey & Company, in the development and execution of business strategies for top-tier biotechnology and pharmaceutical companies, with a focus on oncology. He serves as the Chairman of Revitope Oncology, Inc. He has been a Director of Sierra Oncology, Inc. since October 23, 2017. He serves as a Director of TCR2 Inc. since December 19, 2018. He has been an Independent Director of Epizyme, Inc. since June 9, 2014. He serves as a Member of Scientific Advisory Board of Predictive Biomarker Sciences, Inc. He has been a Director of Gritstone Oncology Inc. since September 2015. He served as a Director at Nodality Inc. He was Director at Cell Design Labs, Inc. until 2017. He was practicing as a Nephrologist (focus on transplantation and immune-mediated glomerulonephritis) at Hammersmith Hospital in London. Dr. Allen received a medical degree from Oxford University. He qualified in Medicine at Oxford University and holds a Ph.D. in Immunology from the Imperial College of Science, Technology and Medicine in London. Dr. Allen obtained Post-Graduate Internal Medicine Qualification as a Member of Royal College of Physicians (MRCP).
Andrew's compensation has increased whilst company is loss making.
Andrew's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Gritstone Oncology management team is about average.
Executive VP of Finance & CFO
Executive VP & CTO
Executive VP of Research & Chief Scientific Officer
Senior Vice President of Human Resources
Executive VP & Chief Business Officer
Executive VP and Global Head of Regulatory Affairs & Quality Assurance
Executive VP & Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Gritstone Oncology board of directors is about average.
Could The Gritstone Oncology, Inc. (NASDAQ:GRTS) Ownership Structure Tell Us Something Useful?
Insider Ownership Of Gritstone Oncology The definition of company insiders can be subjective, and does vary between jurisdictions. … But other times, private equity is selling out, having taking the company public. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.